App-Quantinova.ai

IMED Asia, AstraZeneca, and Dizal (Jiangsu) Pharmaceutical Co., Ltd, Shanghai, China
Guangdong Lung Cancer Institute, Guangdong General Hospital (GGH) and Guangdong Academy of Medical Sciences, Guangzhou, China
Research & Development Information, AstraZeneca, Shanghai, China
China Development Unit, AstraZeneca, Shanghai, China
Department of Respiratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China
Department of Oncology, Cancer Hospital of Jilin Province, Changchun, China
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Respiratory Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Department of Thoracic Oncology, Cancer Center, West China Hospital, West China School of Clinical Medicine, Sichuan University, Chengdu, China
Department of Oncology, Jiangsu Cancer Hospital, Nanjing, China
Department of Oncology, Tangdu Comprehensive Cancer Center, Tangdu Hospital, Xi'an, China
Department of Lung Cancer and Immunology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China

Researchers